secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protagonist Therapeutics, Inc (PTGX)
CIK:        0001377121
Form:       8-K
Filed at:   2021-08-10T23:59:59+00:00
Accession:  0001104659-21-102543
Event type: litigation
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Protagonist Therapeutics resolves rusfertide dispute with Zealand Pharma, reduces royalty and milestone payments by 50%
--------------------------------------------------------------------------------

- Royalty rate on rusfertide net sales reduced by 50% under settlement agreement.
- All development and sales milestone payments for rusfertide reduced by 50%.
- Company to pay $1.0M (Phase 2b milestone) and $1.5M (Phase 3 milestone) within 2 business days.
- Additional $1.5M payment due in August 2022.
- Future development milestones up to $2.75M; sales milestones up to $50M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1377121/000110465921102543/0001104659-21-102543-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1377121/000110465921102543/tm2124650d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-102543

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer